Hympavzi

Marstacimab, the active ingredient in Hympavzi, is a monoclonal antibody presented as a subcutaneous injection for subcutaneous use. It is designed to reduce thrombotic risk in patients who require anticoagulation, such as those undergoing orthopedic surgery or living with atrial fibrillation. GNH USA supplies Hympavzi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Hympavzi (Marstacimab) targets the intrinsic coagulation pathway to prevent clot formation in several high‑risk settings. - Prevention of venous thromboembolism after orthopedic surgery: lowers incidence of deep‑vein thrombosis and pulmonary embolism. - Stroke prevention in non‑valvular atrial fibrillation: reduces risk of ischemic stroke. - Anticoagulation during hemodialysis: provides effective anticoagulation with a potentially lower bleeding profile.

Common Side Effects: - Injection site erythema: mild redness at the administration site. - Headache: transient, mild to moderate intensity. - Nausea: occasional, usually resolves without intervention. - Fatigue: general tiredness reported by some patients.

Serious or Rare Side Effects: - Major bleeding: gastrointestinal or intracranial hemorrhage requiring medical attention. - Allergic reaction: urticaria, angioedema, or anaphylaxis. - Thrombocytopenia: low platelet count observed in rare cases.

Before initiating therapy, clinicians should assess individual bleeding risk and review concomitant medications. - Bleeding risk: monitor for signs of hemorrhage, especially in patients with a history of bleeding disorders. - Renal impairment: evaluate kidney function, as dosing may need adjustment. - Hepatic disease: use caution in patients with liver dysfunction. - Surgery or invasive procedures: consider temporary discontinuation to minimize peri‑operative bleeding. - Pregnancy and lactation: safety not established; weigh potential benefits against unknown risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Marstacimab may interact with other agents that affect hemostasis. Major Interactions (Avoid): - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increased bleeding risk. - Antiplatelet therapy (e.g., aspirin, clopidogrel): additive effect on bleeding. Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate gastrointestinal bleeding. - Herbal supplements with anticoagulant properties (e.g., ginkgo, garlic): monitor for enhanced anticoagulation.